T regulatory cells and attenuated bleomycin-induced fibrosis in lungs of CCR7-/- mice.
BACKGROUND
C-C chemokine receptor (CCR)7 is a regulator of dendritic cell and T cell migration, and its role in tissue wound healing has been investigated in various disease models. We have previously demonstrated that CCR7 and its ligand, chemokine (C-C motif) ligand (CCL)21, modulates wound repair in pulmonary fibrosis (PF) but the mechanism of this is unknown. The objective of this study was to investigate whether the absence of CCR7 protects against bleomycin (BLM)-induced PF. CCR7-/- mice failed to mount a fibrotic pulmonary response as assessed by histologic collagen staining and quantification by hydroxyproline. We hypothesized that the prominent characteristics of CCR7-/- mice, including elevated levels of cytokine and chemokine mediators and the presence of bronchus-associated lymphoid tissue (BALT) might be relevant to the protective phenotype.


RESULTS
Pulmonary fibrosis was induced in CCR7+/+ and CCR7-/- mice via a single intratracheal injection of BLM. We found that the lung cytokine/chemokine milieu associated with the absence of CCR7 correlated with an increase in BALT, and might be attributable to regulatory T cell (Treg) homeostasis and trafficking within the lungs and lymph nodes. In response to BLM challenge, CCR7-/- mice exhibited an early, steady increase in lung CD4+ T cells and increased CD4+ CD25+ FoxP3+ Tregs in the lungs 21 days after challenge. These findings are consistent with increased lung expression of interleukin-2 and indoleamine 2,3-dioxygenase in CCR7-/- mice, which promote Treg expansion.


CONCLUSIONS
Our study demonstrates that the protective phenotype associated with BLM-treated CCR7-/- mice correlates with the presence of BALT and the anchoring of Tregs in the lungs of CCR7-/- mice. These data provide novel evidence to support the further investigation of CCR7-mediated Treg trafficking in the modulation of BLM-induced PF.
Trujillo
Glenda
G
Department of Pathology, University of Michigan, Ann Arbor, MI 48109-2200, USA. hogaboam@med.umich.edu.
Hartigan
Adam J
AJ
Hogaboam
Cory M
CM
Am J Pathol. 2000 Feb;156(2):723-32
10666400
J Pathol. 1996 Mar;178(3):323-9
8778339
J Allergy Clin Immunol. 2008 Sep;122(3):617-24.e6
18672278
Am J Pathol. 2005 Mar;166(3):675-84
15743780
Antioxid Redox Signal. 2008 Feb;10(2):287-301
17961066
J Immunol. 2001 Jun 15;166(12):7556-62
11390511
J Immunol. 2005 Feb 15;174(4):2054-60
15699135
Am J Pathol. 2008 May;172(5):1209-21
18403600
Crit Rev Immunol. 1989;9(2):119-50
2663024
J Clin Oncol. 2008 Sep 20;26(27):4410-7
18802153
Respiration. 2007;74(2):159-69
17108669
J Immunol. 2008 Nov 15;181(10):6984-94
18981118
Am J Respir Crit Care Med. 2009 Jun 15;179(12):1121-30
19342412
J Clin Invest. 2004 Aug;114(3):438-46
15286810
Chest. 2005 Oct;128(4):2971-7
16236974
Nat Immunol. 2010 Jan;11(1):7-13
20016504
Cell. 1999 Oct 1;99(1):23-33
10520991
Proc Am Thorac Soc. 2006 Jun;3(4):357-63
16738201
Nature. 1999 Oct 14;401(6754):708-12
10537110
J Exp Med. 2009 Nov 23;206(12):2593-601
19917776
Am J Pathol. 2007 Apr;170(4):1152-64
17392156
J Immunol. 2006 May 15;176(10):5735-9
16670278
J Immunol. 2010 Jan 15;184(2):895-901
20007536
J Clin Invest. 2007 Mar;117(3):549-56
17332882
Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14098-103
16966615
J Exp Med. 2007 Apr 16;204(4):723-34
17371929
J Clin Pathol. 2006 Jan;59(1):28-39
16394278
Nat Immunol. 2005 Sep;6(9):895-901
16116469
J Exp Med. 2000 May 15;191(10):1755-64
10811868
J Exp Med. 2004 Apr 19;199(8):1113-20
15096537
Ther Adv Respir Dis. 2008 Apr;2(2):75-93
19124361
J Exp Med. 2009 Apr 13;206(4):751-60
19332874
Am J Pathol. 2007 Mar;170(3):843-54
17322370
Immunobiology. 2010 Apr;215(4):321-31
19501934
Eur Respir J. 2007 Jun;29(6):1082-93
17331965
J Immunol. 2009 Jun 1;182(11):6861-9
19454682
Respiration. 2005 Sep-Oct;72(5):490-8
16210888
J Exp Med. 2007 Apr 16;204(4):735-45
17371928
Thorax. 1985 Jun;40(6):405-11
3875162
Cancer Res. 2004 Nov 15;64(22):8451-5
15548717